US initial public offerings by biopharma firms in 2017 have outpaced the number of IPOs completed in the previous year and as investors continue to see big returns the pace isn't likely to slow in 2018.
Celgene won the first approval for a drug developed under its aggressive deal-making strategy in 2017 and several potential blockbusters in its partnered pipeline are edging closer to the market. Ozanimod will soon face regulatory approval, but the next-in-line acquired asset GED-0301 had a major setback. Scrip considers the contribution externally derived products have made – and will make – to Celgene’s business.
Japanese pharma growth is set to decelerate between 2016 and 2026 as an aging population and government pressure on drug prices will temper company revenues. PharmaVitae has analyzed eight leading public pharmaceutical companies in Japan to give a snapshot of the wider industry in the region.
In 2016, the 15 top pharma companies paid their CEOs $276m in total* while those same firms reported a total net income of $96.5bn**. Altogether these companies had a market capitalization of $2,238bn on June 30, 2017**. In this infographic Scrip gives a snapshot of these companies' leaders and the businesses they oversee.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.